TrialThe New England journal of medicine2021
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Sander F Garrelfs et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
298 papers cite itlatest 60 shown
this paperpooled ittrialcites it